COX-2 inhibition in cancer therapeutics: a field of controversy or a magic bullet? (Q35753467)

10 August 2017

1 reference

title

COX-2 inhibition in cancer therapeutics: a field of controversy or a magic bullet? (English)

1 reference

10 August 2017

Michalis V Karamouzis

series ordinal

1

1 reference

PubMed ID

15102586

10 August 2017

Athanasios G Papavassiliou

series ordinal

2

1 reference

PubMed ID

15102586

10 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

Expert Opinion on Investigational Drugs

10 August 2017

1 reference

10 August 2017

13

1 reference

10 August 2017

359-372

1 reference

10 August 2017

4

1 reference

Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment

10 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Cyclooxygenase 2: a molecular target for cancer prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

The coxibs, selective inhibitors of cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

A randomized trial of aspirin to prevent colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

COX-2 inhibitors in cancer treatment and prevention, a recent development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Linkage between retinoid and fatty acid receptors: implications for breast cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Induction of the CBP transcriptional co-activator early during laryngeal carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

COX-2 selective inhibitors: analysis of the renal effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Carcinogen substrate specificity of human COX-1 and COX-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Many actions of cyclooxygenase-2 in cellular dynamics and in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Rofecoxib reduces polyp recurrence in familial polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Cyclo-oxygenase 2 inhibition in colorectal cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Angiogenic markers, neovascularization and malignant deformation of Barrett's esophagus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Prostate cancer: horizons in the development of novel anti-cancer strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Current concepts in cyclooxygenase inhibition in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Cyclooxygenase-2 inhibition improves macrophage function in melanoma and increases the antineoplastic activity of interferon gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Redefining the target: chemotherapeutics as antiangiogenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

The role of cyclooxygenase inhibitors in cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.359

10.1517/13543784.13.4.359

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15102586